Article Abstract

Neurokinin-1 receptor antagonists for chemotherapy-induced nausea and vomiting

Authors: Fahad Aziz

Abstract

Chemotherapy can be a life-prolonging treatment for many cancer patients, but it is often associated with profound nausea and vomiting that is so distressing that patients may delay or decline treatment to avoid these side effects. The discovery of several NK1 receptor antagonists is a big revolution to dealt this problem.

NK1 receptor antagonists prevent both acute and delayed chemotherapy-induced nausea and vomiting (CINV).

These agents act centrally at NK-1 receptors in vomiting centers within the central nervous system to block their activation by substance P released as an unwanted consequence of chemotherapy. By controlling nausea and vomiting, these agents help improve patients’ daily living and their ability to complete multiple cycles of chemotherapy. They are effective for both moderately and highly emetogenic chemotherapy regimens. Their use might be associated with increased infection rates; however, additional appraisal of specific data from RCTs is needed.

Refbacks

  • There are currently no refbacks.